Patents Assigned to WISDOM PHARMACEUTICAL CO., LTD
-
Publication number: 20230357132Abstract: The present disclosure relates to synthesis of an mRNA delivery agent, in particular to a reaction of a related amino compound with ethylene oxide in the presence of ytterbium triflate.Type: ApplicationFiled: November 19, 2021Publication date: November 9, 2023Applicant: WISDOM PHARMACEUTICAL CO., LTD.Inventors: Ping Zou, Zhiwei Zuo, Xiaolong Qiu, Tao Xu, Lin Hu, Lingling Chu, Wenbo Liu
-
Patent number: 11697655Abstract: A preparation method of an intermediate compound of formula II ((1R,2S,3S,4S,5S,6R,11S,14S,17S,19R,21R,23S,25R,26R,27S,31R,34S)-25-[(2S)-2,3-dihydroxy]-2,5-dihydroxy-26-methoxy-19-methyl-13,20-dimethylene-24,35,36,37,38,39-hexaoxane[29.3.1.13,6.14,34.111,14.117,21.023,27]nonatriacontan-8,29-dione) for eribulin mesylate is provided, including subjecting a compound of formula I to a reaction with an additive in the presence of tetra-n-butylammonium fluoride (TBAF). The additive is piperidine hydrochloride or pyridine hydrochloride, and a reaction formula is as follows: The present invention aims to avoid the problem that a traditional synthetic route has a low yield.Type: GrantFiled: November 5, 2021Date of Patent: July 11, 2023Assignee: WISDOM PHARMACEUTICAL CO., LTDInventors: Xiaolong Qiu, Tao Xu, Zhiwei Zuo, Jie Ge, Xinwei Lu, Lingling Chu, Wenbo Liu, Biao Wang, Tingwei Gu, Weiwei Wang, Lin Hu, Ping Zou, Jun Chen, Lei Cao
-
Patent number: 11565990Abstract: A more environmentally friendly synthesis method of 4-bromo-2-(4?-ethoxyphenyl)-1-chlorobenzene with simplified steps provides a more effective synthetic strategy for producing key intermediates of SGLT-2 inhibitors such as dapagliflozin, sotagliflozin, and ertugliflozin. In the presence of trifluoroacetic anhydride, 5-bromo-2-chlorobenzoic acid and phenetole are selected to complete a direct acylation reaction under the catalysis of boron trifluoride diethyl etherate, and triethylsilane is added thereinto without treatment for one-pot reaction to obtain a target compound 4-bromo-2-(4?-ethoxyphenyl)-1-chlorobenzene.Type: GrantFiled: June 9, 2021Date of Patent: January 31, 2023Assignee: WISDOM PHARMACEUTICAL CO., LTDInventors: Lin Hu, Tao Xu, Xiaolong Qiu, Xiaoyue Li, Zhiwei Zuo, Wenbo Liu, Lingling Chu, Ximeng Yuan, Ping Zou
-
Publication number: 20230010367Abstract: A related substance of linagliptin intermediate 2-(chloromethyl)-4-methylquinazoline, 4,4?-(2-methylpropane-1,3-diyl)bis(2-(chloromethyl)quinazoline) and a method for synthesizing the related substance (impurity) by reacting 2-(chloromethyl)-4-methylquinazoline with acetaldehyde under an alkaline condition and a purification method are provided. The preparation method is simple and convenient to operate, short in reaction time, high in product purity, and high in yield. The synthesized related substance can be used for qualitative and quantitative analysis of the linagliptin intermediate 2-(chloromethyl)-4-methylquinazoline and API impurities of linagliptin, so that the medication safety of the linagliptin is improved.Type: ApplicationFiled: June 9, 2021Publication date: January 12, 2023Applicant: WISDOM PHARMACEUTICAL CO., LTDInventors: Xiaolong QIU, Hu WANG, Tao XU, Lin HU, Ping ZOU, Zhiwei ZUO, Wenbo LIU, Lingling CHU
-
Publication number: 20220402933Abstract: A preparation method of an intermediate compound of formula II ((1R,2S,3S,4S,5S,6R,11S,14S,17S,19R,21R,23S,25R,26R,27S,31R,34S)-25-[(2S)-2,3-dihydroxy]-2,5-di hydroxy-26-methoxy-19-methyl-13,20-dimethylene-24,35,36,37,38,39-hexaoxane[29.3.1.13,6.14,34.111,14.117,21.023,27]nonatriacontan-8,29-dione) for eribulin mesylate is provided, including subjecting a compound of formula I to a reaction with an additive in the presence of tetra-n-butylammonium fluoride (TBAF). The additive is piperidine hydrochloride or pyridine hydrochloride, and a reaction formula is as follows: The present invention aims to avoid the problem that a traditional synthetic route has a low yield.Type: ApplicationFiled: November 5, 2021Publication date: December 22, 2022Applicant: WISDOM PHARMACEUTICAL CO., LTDInventors: Xiaolong QIU, Tao XU, Zhiwei ZUO, Jie GE, Xinwei LU, Lingling CHU, Wenbo LIU, Biao WANG, Tingwei GU, Weiwei WANG, Lin HU, Ping ZOU, Jun CHEN, Lei CAO
-
Publication number: 20220331272Abstract: Use of a flurbiprofen axetil (FPA) in preparing a pharmaceutical composition for fever relief in a patient through an intravenous administration route is provided, where the pharmaceutical composition includes FPA at a content of 10 mg to 40 mg, preferably 10 mg to 35 mg, 15 mg to 35 mg, and 15 mg to 30 mg, 15 mg, and 30 mg. The pharmaceutical composition can be safely and effectively used for fever relief in an adult patient. Surprisingly, the pharmaceutical composition has a comparable antipyretic effect and duration to a pharmaceutical composition with high-content FPA, but the pharmaceutical composition with low-content FPA has less adverse reactions. Compared with ibuprofen injections, a single administration of the low-dosage FPA provided by the present disclosure can maintain an antipyretic effect for 6 hours to 10 hours or more, which significantly reduces the administration frequency and improves the compliance of a patient.Type: ApplicationFiled: September 22, 2020Publication date: October 20, 2022Applicant: WISDOM PHARMACEUTICAL CO., LTDInventors: Jinping LIN, Huaxian SONG, Zhongli LI, Jingwen LIN, Zhengwei HU
-
Publication number: 20220267238Abstract: A more environmentally friendly synthesis method of 4-bromo-2-(4?-ethoxyphenyl)-1-chlorobenzene with simplified steps provides a more effective synthetic strategy for producing key intermediates of SGLT-2 inhibitors such as dapagliflozin, sotagliflozin, and ertugliflozin. In the presence of trifluoroacetic anhydride, 5-bromo-2-chlorobenzoic acid and phenetole are selected to complete a direct acylation reaction under the catalysis of boron trifluoride diethyl etherate, and triethylsilane is added thereinto without treatment for one-pot reaction to obtain a target compound 4-bromo-2-(4?-ethoxyphenyl)-1-chlorobenzene.Type: ApplicationFiled: June 9, 2021Publication date: August 25, 2022Applicant: WISDOM PHARMACEUTICAL CO., LTDInventors: Lin HU, Tao XU, Xiaolong QIU, Xiaoyue LI, Zhiwei ZUO, Wenbo LIU, Lingling CHU, Ximeng YUAN, Ping ZOU
-
Patent number: 11001604Abstract: A method for preparing tulathromycin, and two intermediate compounds shown in formula V and formula VI are provided.Type: GrantFiled: February 5, 2018Date of Patent: May 11, 2021Assignee: WISDOM PHARMACEUTICAL CO., LTD.Inventors: Ping Zou, LingLing Chu, Xiaolong Qiu, Lin Hu, ChengLiang Zhang, XiangJun Zeng, ShaoHua Gou, ZhongPing Wu, Wei Shen, Jian Fu, Ming Xu, Ping Wang, XinGang Zhang, GuangHao Shi, JunQiang Wang, Jun Chen, Lei Cao
-
Publication number: 20200354396Abstract: A method for preparing tulathromycin, and two intermediate compounds shown in formula V and formula VI are provided.Type: ApplicationFiled: February 5, 2018Publication date: November 12, 2020Applicant: WISDOM PHARMACEUTICAL CO., LTDInventors: Ping ZOU, LingLing CHU, XiaoLong QIU, Lin HU, ChengLiang ZHANG, XiangJun ZENG, ShaoHua GOU, ZhongPing WU, Wei SHEN, Jian FU, Ming XU, Ping WANG, XinGang ZHANG, GuangHao SHI, JunQiang WANG, Jun CHEN, Lei CAO